Mounjaro

Eli Lilly raised its full-year revenue forecast on Thursday, Oct. 29, after strong demand for its tirzepatide drugs Mounjaro and Zepbound pushed third-quarter results well above Wall Street expectations. The company now expects 2026 revenue of $91 billion to $92…